Podcasts about radiotherapy

It's a rather hoarse and croaky Dave this month, but that's not gonna stop him. He's back to preside over another 60 minutes of the good stuff, that is actually the 15th anniversary his acclaimed Radio Therapy show. That's a decade and a half at the coalface of Electronic Music Radio! Respect is due

It's a rather hoarse and croaky Dave this month, but that's not gonna stop him. He's back to preside over another 60 minutes of the good stuff, that is actually the 15th anniversary his acclaimed Radio Therapy show. That's a decade and a half at the coalface of Electronic Music Radio! Respect is due

Send us a textJoin us for an episode looking at the role of radiotherapy in cancer treatment.We discuss the principles of radiotherapy with Dr Grant Stewart who has 20 years experience with radiotherapy treatments.This is a great episode for anyone wanting to understand the principles of radiotherapy.IF you are a patient wanting to understand your treatment or a doctor or nurse wanting to know more about radiotherapy please check this out!

Dr Tom Bird, Consultant Clinical Oncologist at Bristol Haematology and Oncology Center, UK, discusses how he treats people with oesophageal cancer.  This includes, locally advanced adenocarcinoma including staging, systemic and radiotherapy treatment, metastatic/recurrent adenocarcinoma (which includes an update on the treatment of gastric cancer treatment -alongside GOJ cancer -that we discussed in the prior gastric cancer podcast) including both systemic agents and palliative radiotherapy, and how treatment differs with squamous cell histology. This podcast is an overview of the current oncology treatment of oesophageal cancer at a registrar level and is aimed at those training in oncology in the UK. Your host is Dr Alison Cameron, Consultant Clinical Oncologist, Bristol, UK.

Dave's back and we hope you've got your factor 50 ready as it's a hot one!

Dave's back and we hope you've got your factor 50 ready as it's a hot one!

Dave's back with another freshly baked batch of electronic goodness, carefully crafted for your delight and delectation and he's saved you a spot, right by the the speaker! Come on and get some! Tracklist.. 1. Adam Ten & Mita Gami feat. Marina Maximilian ‘Million Pieces' [Maccabi House] 2. Ivory (IT) ‘You' [ICONYC] 3. Garla & Meloko ‘Take Down' (Marc Gonen) [Azzur] 4. Yamil ‘Eternal Spring' (Elif) [Pieces of Life] 5. Carleo ‘Wild' (EdOne) [Ilinx] 6. Andrew Sant feat. Pauline Taylor ‘Rollin On' (Dub) [Selador] 7. D-Formation & Darksidevinyl ‘Reach Out' [Beatfreak] 8. Siphe Tebeka ‘Fungweni' [Bridges For Music] 9. Rufus Du Sol ‘Inhale' (Sean Doron) [Rose Avenue] 10. Paons & Barbabo ‘Chordura' (Stil & Bense) [Manual Music] 11. Rebel Of Sleep ‘Distant Thoughts' [Fenestra] 12. D-Nox ‘Heartbeat' [Sprout] This show is syndicated & distributed exclusively by Syndicast. If you are a radio station interested in airing the show or would like to distribute your podcast / radio show please register here: https://syndicast.co.uk/distribution/registration

Dave's back with another freshly baked batch of electronic goodness, carefully crafted for your delight and delectation and he's saved you a spot, right by the the speaker! Come on and get some! Tracklist.. 1. Adam Ten & Mita Gami feat. Marina Maximilian ‘Million Pieces' [Maccabi House] 2. Ivory (IT) ‘You' [ICONYC] 3. Garla & Meloko ‘Take Down' (Marc Gonen) [Azzur] 4. Yamil ‘Eternal Spring' (Elif) [Pieces of Life] 5. Carleo ‘Wild' (EdOne) [Ilinx] 6. Andrew Sant feat. Pauline Taylor ‘Rollin On' (Dub) [Selador] 7. D-Formation & Darksidevinyl ‘Reach Out' [Beatfreak] 8. Siphe Tebeka ‘Fungweni' [Bridges For Music] 9. Rufus Du Sol ‘Inhale' (Sean Doron) [Rose Avenue] 10. Paons & Barbabo ‘Chordura' (Stil & Bense) [Manual Music] 11. Rebel Of Sleep ‘Distant Thoughts' [Fenestra] 12. D-Nox ‘Heartbeat' [Sprout] This podcast is hosted by Syndicast.

In 1991, Professor Sten Nilsson and his PhD student Bo Lennernäs realised that the prostate, contrary to prevailing beliefs, is a mobile organ. A study confirmed their observations, and the new findings were included in Bo Lennernäs's doctoral thesis in 1995. The discovery quickly influenced prostate cancer radiotherapy practices across the world. In the papers of the thesis, they also demonstrated that it was possible to track the prostate's movements in a phantom model by inserting a small magnet that transmitted signals to an external receiver. These two findings led to the founding of Micropos Medical AB. Discovering more about Prostate Cancer Sten Nilsson, now a retired senior consultant at Karolinska University Hospital and Professor Emeritus at the Karolinska Institute, has dedicated over 40 years of his career to oncology, with a particular focus on prostate cancer. He has been involved in numerous pioneering research projects and developed new, crucial treatment concepts that are now used globally. Decades of Development When Sten Nilsson treated his first prostate cancer patients in the late 1970s, very few were cured. The tools and techniques for diagnosing and assessing whether the cancer was local or had spread were insufficient, as was radiotherapy. The available X-ray technology could visualise the pelvic skeleton but not the prostate, meaning its position had to be estimated based on the anatomy of the pelvic bones. Radiotherapy was cumbersome and time-consuming to administer, with limited impact on the tumours. "Patients whose cancer was assessed as local received radiotherapy with what we called a 'curative intention'. But in practice, most returned after a while, and the disease remained - eventually spreading," says Sten Nilsson. In the mid-1980s, surgery for localised prostate cancer began delivering better outcomes than radiotherapy. However, radiotherapy also advanced rapidly. Computed tomography (CT) became available, allowing the prostate and sometimes the tumour area to be visualised, which created entirely new conditions for treatment. Subsequently radiotherapy equipment, radiobiological research, and various imaging technologies like CT, MRI, ultrasound and others, also underwent enormous development. The 1990s saw the introduction of high-dose-rate brachytherapy (HDR-BT), a method to which Sten Nilsson made significant contributions. It involves inserting 15-20 hollow needles through the skin into the prostate, through which radiation is delivered. Today, HDR-BT is often combined with external beam radiotherapy in cases of locally advanced prostate cancer. A Discovery that Overturned Accepted Knowledge It was during HDR-BT procedures in 1991 that Sten Nilsson and Bo Lennernäs discovered that the prostate changes position under various conditions. "We used ultrasound to correctly position the needles in the prostate. We then observed that if a patient was anxious, perhaps coughed, raised an arm to scratch their head or simply spoke, the prostate moved. It was a true 'aha' moment. The common belief around the world was that the prostate is firmly anchored in the pelvis. We immediately realized that we had to find a way to describe and document the movement of the prostate, how much and in which directions the prostate moved", Sten Nilsson explains. Years earlier, he had treated prostate cancer patients by implanting radioactive gold seeds into the prostate to deliver a strong local radiation dose. The method was abandoned when seed production ceased, but the treated patients retained the seeds (they were not surgically removed) - creating an opportunity to document the discovery of prostate movement. "The gold seeds, and thus the prostate's position, are visible on X-rays. We called in a number of the former patients and took images under various conditions. For example, while straining versus relaxing, with full versus emptied bladder, and so forth. We found that the prostate frequently moved by ...

Johann Ilgenfritz's life changed in 2011 when he had a heart attack and six months later was diagnosed with cancer. After unsuccessful Radio Therapy he researched for a cure, soon realizing that that there was no central point for reliable online health information. He decided to create a platform and launched UK Health Radio, while still fighting cancer. After overcoming cancer through nutritional and lifestyle changes, he earned the title "The Curator of Health Expertise" from the press. His guiding principle is simple: "Good health is a choice." Initially, he saw cancer as the root of his illness but later realized it was merely a symptom of an already unwell body. He understood that by addressing the underlying cause, he could transform the outcome. With this vision, UK Health Radio (https://ukhealthradio.com/) has embraced a clear mission: to inspire and empower people to take responsibility for their own health. This does not mean taking your health into your own hands, but to be part of the process of attaining and/or keeping your health freedom. It is all about being informed, being empowered, taking action and being healthy! UK Health Radio delivers information through 41 shows airing 24/7, reaching over 1.5 million very dedicated listeners and is now also available on 11 podcast platforms worldwide. In February of 2024, Johann created The Alkaline Collective Mastermind (https://alkaline-collective.com/), a dedicated online community for those battling cancer, aiming to prevent it, or striving to stop it's recurrence. Designed for individuals who are committed to hold themselves accountable, and seek a comprehensive toolbox of resources.

In this episode of The Moss Report, Ben Moss speaks with Dr. Ralph Moss about a little-known natural compound that may have big implications: Modified Citrus Pectin (MCP). A recent clinical trial in Israel found that MCP helped slow PSA doubling time in men with recurrent prostate cancer—suggesting it may offer real, measurable support for patients after treatment. Ben and Ralph trace the story from its origins in the 1990s through modern-day research, digging into how MCP works by targeting Galectin-3, a molecule tied to inflammation and cancer spread. Along the way, they highlight the researchers who kept this idea alive, including Dr. Kenneth Pienta and Dr. Isaac Eliaz, and ask why this research isn't more widely known. It's an honest, science-based conversation about where evidence and action meet—and how natural approaches might still be flying under the radar. Link to the full article with transcript, slide presentation, links and cited studies. https://www.themossreport.com/mcp-podcast/ Products mentioned in this podcast: Pectasol-C – https://econugenics.com/?a_aid=TMR Mycolife – The Moss Method Mushroom Formula – https://mycolife.us/product/the-moss-method-mushroom-formula/ Links and Resources:

·       In this podcast a patient with sarcoma and a specialist sarcoma nurse discuss the patient's journey from initial diagnosis through to treatment and recovery. They will also discuss the physiological, emotional and mental impact that sarcoma had, as well as the critical role of the cancer nurse specialist within the treatment plan, alongside a patient support group. Listeners to the podcast will gain a better understanding of the challenges in diagnosing soft-tissue sarcoma, the tools that are already available to assist physicians in diagnosis, and the importance of providing patients with clear information throughout the treatment journey.   This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the  Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00342-6. All conflicts of interest can be found online. This podcast is intended for medical professionals.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Dave's back and in particularly jovial spirits after celebrating his birthday this week (and his football team winning promotion), so let's get this party started shall we? Broadcasting via the magical medium of linked computers, this is Radio Therapy! Tracklist.. 1. Notre Dame ‘My Soul' [Kitsuné] 2. Adriatique x JAiMES x Samm ‘Back To Life' [X Recordings] 3. Tee Mango ‘Moonshots' [Kompakt] 4. Radeckt ‘Otun' [Human By Default] 5. Ivory ‘Hypno Dance' [Exit Strategy] 6. Fat Cosmoe & My Flower ‘Wanna More' [Habitat] 7. Impérieux ‘Still Minus' [Keller] 8. Chemo ‘Glock 43' [Marginalia] 9. Sasha & Joseph Ashworth ‘HiFiHi' [Last Night On Earth] 10. AIKON ‘Ngoma' [Monaberry] 11. Mind Against ‘Babylon' [Habitat] 12. Tim Engelhardt & Solique ‘Symmetry' [Habitat] 13. Danny Howells ‘Thrunk' [Rekids] 14. Tommy Gustav ‘Nobody Else' [Deepalma] This show is syndicated & distributed exclusively by Syndicast. If you are a radio station interested in airing the show or would like to distribute your podcast / radio show please register here: https://syndicast.co.uk/distribution/registration

Dave's back and in particularly jovial spirits after celebrating his birthday this week (and his football team winning promotion), so let's get this party started shall we? Broadcasting via the magical medium of linked computers, this is Radio Therapy! Tracklist.. 1. Notre Dame ‘My Soul' [Kitsuné] 2. Adriatique x JAiMES x Samm ‘Back To Life' [X Recordings] 3. Tee Mango ‘Moonshots' [Kompakt] 4. Radeckt ‘Otun' [Human By Default] 5. Ivory ‘Hypno Dance' [Exit Strategy] 6. Fat Cosmoe & My Flower ‘Wanna More' [Habitat] 7. Impérieux ‘Still Minus' [Keller] 8. Chemo ‘Glock 43' [Marginalia] 9. Sasha & Joseph Ashworth ‘HiFiHi' [Last Night On Earth] 10. AIKON ‘Ngoma' [Monaberry] 11. Mind Against ‘Babylon' [Habitat] 12. Tim Engelhardt & Solique ‘Symmetry' [Habitat] 13. Danny Howells ‘Thrunk' [Rekids] 14. Tommy Gustav ‘Nobody Else' [Deepalma] This podcast is hosted by Syndicast.

HEAT fans call in for some good ole Radio Therapy as we trauma bond over our HEAT related pain.

Send us a textThis recording features audio versions of May 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Recurrent Portal Hypertension after Liver Transplant: Impact on Survival and the Role of Transjugular Intrahepatic Portosystemic Shunt Creation in Management ReadNontarget Hemangioma Size Reduction after Bleomycin–Ethiodized Oil Embolization of Primary Hepatic Hemangioma ReadMR–Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma ReadEmbolotherapy for Pulmonary Arteriovenous Malformations in the Pediatric Population with Hereditary Hemorrhagic Telangiectasias—A Retrospective Case Series ReadEffects of Prophylactic Coil Embolization of Pelvic Arteries on Surgical Outcomes in Hemodynamically Stable Patients with Complex Acetabular Fractures ReadPercutaneous Ablation versus Radiotherapy for Pain Related to Bone and Soft Tissue Malignancies: A Multipayor Database Analysis of Outcomes ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Sonya Choe, University of California Riverside School of MedicineAudio editor:Sonya Choe, University of California Riverside School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Ahmed Alzubaidi, Wayne State University School of MedicineIpek Midillioglu, Western University of Health Sciences, College of Osteopathic MedicineNate Wright, Warren Alpert Medical School of Brown University Sanya Dhama, University of California Riverside School of MedicineTiffany Nakla, Touro University Nevada College of Osteopathic MedicineKalei Hering, Harvard Medical School SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

This podcast is sponsored by Elekta

Editor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.

Dutifully making some sense of the madness in a crazy world, Dave's back with another oasis of positive dance floor vibes. Making life a little sweeter, one tune at a time, this is Radio Therapy... Tracklist… 1. Quivver x Dave Seaman ‘The Promise' [Sudbeat] 2. DJ Koze ‘Buschtaxi' [Pampa] 3. Monkey Safari ‘Searching For Myself' [Good Vibes From Paradise] 4. Marc Werner ‘Omar' [Didschn] 5. Animal Trainer ‘3001' [Hive Audio] 6. Ezequiel Arias ‘Perfect Dream' [Sudbeat] 7. Hylia ‘Try Again' [Eastern Standard] 8. Tim Engelhardt x Solique ‘Take Control' [Habitat] 9. Excuse The Past ‘Falling Deep' [Monaberry] 10. Rolasoul ‘Everything Everywhere' [Plastic Fantastic] 11. Quivver x Dave Seaman ‘Cowbells of Nuneaton' [Sudbeat] 12. Harald Björk 'Schwarm' [Kranglan Broadcast] An extended version of Radio Therapy is available every month via subscription. For further details head to... https://www.mixcloud.com/daveseaman/select/ This show is syndicated & distributed exclusively by Syndicast. If you are a radio station interested in airing the show or would like to distribute your podcast / radio show please register here: https://syndicast.co.uk/distribution/registration

Dutifully making some sense of the madness in a crazy world, Dave's back with another oasis of positive dance floor vibes. Making life a little sweeter, one tune at a time, this is Radio Therapy... Tracklist… 1. Quivver x Dave Seaman ‘The Promise' [Sudbeat] 2. DJ Koze ‘Buschtaxi' [Pampa] 3. Monkey Safari ‘Searching For Myself' [Good Vibes From Paradise] 4. Marc Werner ‘Omar' [Didschn] 5. Animal Trainer ‘3001' [Hive Audio] 6. Ezequiel Arias ‘Perfect Dream' [Sudbeat] 7. Hylia ‘Try Again' [Eastern Standard] 8. Tim Engelhardt x Solique ‘Take Control' [Habitat] 9. Excuse The Past ‘Falling Deep' [Monaberry] 10. Rolasoul ‘Everything Everywhere' [Plastic Fantastic] 11. Quivver x Dave Seaman ‘Cowbells of Nuneaton' [Sudbeat] 12. Harald Björk 'Schwarm' [Kranglan Broadcast] An extended version of Radio Therapy is available every month via subscription. For further details head to... https://www.mixcloud.com/daveseaman/select/ This podcast is hosted by Syndicast.

Speaking to Steve Roest, CEO of PocDoc this week are Kelly and Morgan the co-founders of Perci Health, the UK's largest virtual cancer clinic, delivering early detection, comprehensive cancer management, and survivorship support. They are on a mission to radically improve global cancer outcomes.After you've done the standard treatments, it can often feel like you're being kicked out without any plan. That's where Kelly and Morgan's company, Perci Health, comes in. Looking at NHS-approved clinical support, mental health support, physiotherapy and nutrition. Their view is that more and more people will be living WITH cancer, not dying FROM cancer, so focusing on helping people live the best life is their mission.

BONUS TRACK    Síguenos en:  web: www.cirugiadocente.com Instagram: @cirugiadocente Podcast: "Entre Cirugías" y "Pioneros"

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

BUFFALO, NY - March 21, 2025 – A new #editorial was #published in Oncotarget, Volume 16, on March 13, 2025, titled “No disease left behind." In this editorial, Dr. Muzamil Arshad from the University of Chicago Medical Center and colleagues highlight a growing concern in cancer care: radiotherapy may leave behind microscopic cancer even when scan images suggest the tumor is gone. The authors argue that this “residual disease” is more common than expected and is linked to worse long-term outcomes. Their perspective calls for a rethinking of how treatment success is judged and how cancer is followed up after therapy. Radiotherapy, especially a form known as stereotactic ablative radiotherapy (SABR), is widely used to treat cancers in the lung, liver, prostate, and other organs. SABR delivers high-dose radiation with outstanding precision and often shows excellent results on scans. However, the authors highlight that relying only on imaging may not provide a complete picture. Months or even years later, follow-up biopsies frequently reveal cancer cells that scan imaging tests were unable to identify. “Residual cancer is identified on histology in 40% of lung, 57–69% of renal cell, 7.7–47.6% of prostate and 0–86.7% of hepatocellular carcinoma.” This gap between what scans show and what tissue analysis finds can have serious consequences. Studies across several cancer types have shown that patients with residual disease—even if small—are more likely to experience cancer recurrence and shorter survival. This pattern holds true for rectal, cervical, prostate, and liver cancers, among others. In some cases, not destroying the tumor completely may allow it to spread to distant organs. The authors point out that a complete response on scan imaging does not necessarily indicate the complete disappearance of the tumor. This mismatch can mislead both clinicians and patients into thinking treatment was more successful than it truly was. The editorial encourages more regular use of biopsy-based tests and new strategies to increase the true effectiveness—or “ablative power”—of SABR. They also discuss promising approaches to improve outcomes, including increasing radiation doses and combining radiotherapy with other therapies, such as immune checkpoint inhibitors. While some trials have shown better tumor control with these combinations, results have not been consistent, and more research is needed to refine these strategies. In summary, this editorial encourages the cancer care community to look beyond the scan images. Residual cancer may remain even when imaging looks clear, and recognizing this hidden threat is key to improving long-term outcomes. The goal is not just to shrink tumors on screen but to fully eliminate the disease. DOI - https://doi.org/10.18632/oncotarget.28700 Correspondence to - Muzamil Arshad - muzamil.arshad@uchicagomedicine.org Video short - https://www.youtube.com/watch?v=XC0XNjJjC2o Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Calling all music enthusiasts of a dance floor persuasion, roll up, rollup, cos Dave's back with some more of those block rocking' beats! So dust off your dancing shoes party people, it's Radio Therapy time. Get it down ya! Tracklist... 1. Clavis & Kuba ‘Drifting' [Lossless] 2. AWEN x Moullinex x GPU Panic x Xinobi ‘The Wave' (Sebastien Leger) [Discotexas] 3. Aikon x Dave Seaman ‘Promise You' [Selador] 4. Bebetta ‘House Of Yes' [Eating People] 5. Claudio Ricci ‘The Love We Share' [Urge To Dance] 6. Spada feat. Nomvula SA ‘Siclea Ushwele' (Jonathan Kaspar) [Siamese] 7. Klement Bonelli ‘Sauvage' [Tinnit] 8. Jonathan Cowan ‘ Slater' [Selador] 9. Yousef ‘Teen Anger' [Renaissance] 10. Danny Howells ‘Stereodrama' (Aubrey Fry & Nick Stoynoff) [Selador] 11. EdOne & Yet More ‘Everybody Love' (Musumeci) [Surrealism] 12. Tom Westy ‘Nightfall' [Terminal 1] This show is syndicated & distributed exclusively by Syndicast. If you are a radio station interested in airing the show or would like to distribute your podcast / radio show please register here: https://syndicast.co.uk/distribution/registration

Calling all music enthusiasts of a dance floor persuasion, roll up, rollup, cos Dave's back with some more of those block rocking' beats! So dust off your dancing shoes party people, it's Radio Therapy time. Get it down ya! Tracklist... 1. Clavis & Kuba ‘Drifting' [Lossless] 2. AWEN x Moullinex x GPU Panic x Xinobi ‘The Wave' (Sebastien Leger) [Discotexas] 3. Aikon x Dave Seaman ‘Promise You' [Selador] 4. Bebetta ‘House Of Yes' [Eating People] 5. Claudio Ricci ‘The Love We Share' [Urge To Dance] 6. Spada feat. Nomvula SA ‘Siclea Ushwele' (Jonathan Kaspar) [Siamese] 7. Klement Bonelli ‘Sauvage' [Tinnit] 8. Jonathan Cowan ‘ Slater' [Selador] 9. Yousef ‘Teen Anger' [Renaissance] 10. Danny Howells ‘Stereodrama' (Aubrey Fry & Nick Stoynoff) [Selador] 11. EdOne & Yet More ‘Everybody Love' (Musumeci) [Surrealism] 12. Tom Westy ‘Nightfall' [Terminal 1] This podcast is hosted by Syndicast.

Are you confident in managing patients on bisphosphonates or biologics? Which medications increase the risk of medication-related osteonecrosis of the jaw (MRONJ)? How do you decide when to extract a tooth and when to refer to a specialist? In this episode, Jaz is joined by oral surgery consultant Dr. Pippa Cullingham to explore the complexities of MRONJ. They break down the key risk factors, share expert advice on when to proceed with extractions, and discuss the latest guidelines for managing patients at risk. They also discuss the importance of early assessment - by identifying at-risk teeth early, you can help prevent serious complications and ensure the best outcome for your patients. https://youtu.be/KnQoI8Z-FhM Watch PDP215 on Youtube Protrusive Dental Pearl: it is so important to assess patients before they start taking high-risk medications like bisphosphonates or biologics, using radiographs to identify potential issues. Extractions should ideally be done before medication starts to avoid complications, as MRONJ risk increases once treatment begins. Key Takeaways: Medication-related osteonecrosis of the jaw concerns medications other than bisphosphonates. Risk assessment is crucial when considering dental extractions for patients on certain medications. Guidelines from the Scottish Dental Clinical Effectiveness Partnership are valuable resources for dentists. Higher-risk patients require careful management and communication with their medical teams. Denosumab has a different risk profile compared to bisphosphonates. Patients on long-term bisphosphonates may still have risks even after stopping the medication. Dentists should feel empowered to manage certain extractions in primary care with proper guidance. The decision to extract a tooth should weigh the risks and benefits for the patient. Always assess the patient's risk before extraction. Eight weeks is a critical time for assessing healing. Antibiotics are not recommended for preventing MRONJ in the UK. Radiotherapy history significantly impacts extraction risk. Referral to specialists may be necessary for high-risk patients. Highlights of this episode: 02:15 Protrusive Dental Pearl 03:52  Interview with Dr. Pippa Cullingham: Insights and Experiences 06:40 Medications and Their Risks 10:02 MRONJ: Incidence and Prevalence 13:13 Biologics and other medications 14:19 Guidelines and Best Practices 17:22 Managing High-Risk Patients 25:03 Prophylactic Antibiotics  26:55 Risk Assessment 28:47 Radiotherapy & ORN Risk 31:49 Tips and Key Takeaways 33:32 New Medications & Prevention Strategies For the best approach to managing MRONJ, check the SDCEP Guidelines and the American White Paper. This episode is eligible for 0.5 CE credits via the quiz on Protrusive Guidance.  This episode meets GDC Outcomes B and C. AGD Subject Code: 730 ORAL MEDICINE, ORAL DIAGNOSIS, ORAL PATHOLOGY (Diagnosis, management and treatment of oral pathologies) Dentists will be able to - 1. Be aware of the medications that increase the risk of MRONJ. 2. Learn how to assess the risk of MRONJ in patients, particularly before starting high-risk medications. 3. Understand when to proceed with extractions and when to refer patients to specialists for management. If you liked this episode, check out PDP206 - White Patches

BUFFALO, NY — March 3, 2025 — A new #research paper was #published in Aging (Aging-US) on February 27, 2025, as the #cover of Volume 17, Issue 2, titled “Variability in radiotherapy outcomes across cancer types: a comparative study of glioblastoma multiforme and low-grade gliomas.” An international research team, led by first author Alexander Veviorskiy from Insilico Medicine AI Limited, Abu Dhabi, UAE, and corresponding author Morten Scheibye-Knudsen from the Center for Healthy Aging, University of Copenhagen, investigated how radiotherapy affects survival in different types of cancer, with a special focus on glioblastoma multiforme (GBM) and low-grade gliomas (LGG). Their findings reveal that radiotherapy has opposite effects in GBM and LGG patients. The study highlights key biological differences between these brain cancer types, emphasizing the need for personalized treatment strategies. Radiotherapy is a standard treatment for many tumors, but its effectiveness varies widely depending on the type of cancer. The researchers began by analyzing data from 32 cancer types using information from The Cancer Genome Atlas (TCGA). They then focused on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), two types of brain cancer with distinct biological behaviors. GBM is an aggressive cancer with poor survival rates, whereas LGG progresses more slowly and often has a better prognosis. “GBM and LGG are particularly interesting to study together because GBM often originates from a preexisting LGG, representing a progression from a lower-grade to a higher-grade malignancy.” The results revealed a striking contrast: patients with GBM who received radiotherapy lived longer, whereas those with LGG had shorter survival times after treatment. To understand the reasons behind this, the researchers analyzed gene expression and signaling pathways. They identify several biological processes that may influence radiotherapy outcomes. For example, GBM tumors have weaker DNA repair mechanisms, making them more vulnerable to radiation-induced damage, which allows radiotherapy to effectively kill cancer cells. In contrast, LGG tumors have stronger DNA repair systems, helping cells survive radiation better and potentially reducing the treatment's effectiveness. Additionally, differences in immune system activity and genetic mutations—such as EGFR alterations—were linked to worse survival in LGG patients who received radiotherapy. These findings highlight the need for a more personalized approach to treating brain cancer. The study proposes that a universal approach to radiotherapy is not appropriate, particularly for patients with LGG. Instead, personalized treatment strategies based on genetic and molecular characteristics could improve patient survival outcomes. The research also raises the possibility of combining radiotherapy with targeted therapies, such as immune-boosting therapies or DNA repair inhibitors, to enhance its effectiveness. In conclusion, this study highlights the complexity of brain cancer treatment and the need for further research to refine therapeutic strategies. By understanding the molecular and genetic differences between the different types of cancers, more effective and personalized approaches can be developed to improve survival and quality of life for brain cancer patients. DOI - https://doi.org/10.18632/aging.206212 Corresponding author - Morten Scheibye-Knudsen - mscheibye@sund.ku.dk Video short - https://www.youtube.com/watch?v=j91rzDJHXTE Visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Jane McLelland is a 3 time cancer survivor and advocate of a "middle path" - combining traditional proven treatments like chemotherapy and radiotherapy with previously unheralded approaches to nutrition and other areas of care.Russell Hopson is an established leader in the global advertising industry, having led agencies in the UK and Australia. He is currently in a drug trial having been diagnosed with Stage 4 Pancreatic Cancer in April 2023. He was given between 4 and 6 months to live and 2 years later, he credits Jane's mindset with much of his positive approach to tackling his cancer.This show is a very emotional but balanced approach to a sensitive subject.

Accelerators co-host Dr. Matt Spraker is joined by radiation oncologists Drs. Bobby Koneru and Mudit Chowdhary for an update on low dose radiotherapy for osteoarthritis! Dr. Koneru is a radiation oncologist in Freeport, IL and prolific social media educator on benign indications. Dr. Chowdhary is a radiation oncologist at Northside Hospital in Atlanta, Georgia, and a friend of TAP (see his prior episodes).We start by discussing their ASTRO 2024 panel on benign indications for radiotherapy; it sounds like there was a lot of knowledge sharing among those getting started with these treatments.Bobby and Mudit share how they built a referral network for their successful practices.We close by discussing some practical tips and recommended educational resources. Here are some other things we discussed in the show, or links that may be helpful in building your benign radiotherapy practice: Matt's LDRT & Benign Resource ListRadiotherapy Academy for Benign Diseases (RT-ABC)Makarova et al., RCT showing LDRT reduces disability risk in OAEnglish Translation of the DEGRO-AG “Radiotherapy of Benign Diseases”TAP reviews LDRT with Dr. Austin Dove Alvarez et al., Radiotherapy for Benign Conditions Contouring AtlasLDRT for arthritis PRIMR videoThe Accelerators Podcast is a Photon Media production. 

In celebration of reaching the milestone of our 300th edition of the Selador Sessions, Dave's back with another Radio Therapy, plus as an added bonus, Steve has made a special SS300 Mix full of Selador classics, old and new, that will be available via the Selador Bandcamp and YouTube Pages. Head to seladorrecordings.com for further details. Tracklist.. 1. Leo Cepeha ‘Sirolo' [Monaberry] 2. Dilby ‘Closer' [Selador] 3. Four Candles & Steve Parry ‘Soul Repeat' [Selador] 4. Danny Howells ‘Cygnet' [Selador] 5. Just Her & Nolan ‘Howler'[Last Night On Earth] 6. Cortona ‘Xtaci' [Bedrock] 7. Quattrovalvole ‘Passenger Exit' (Murat Uncuoglu) [Isolate] 8. Grezzer ‘Lost Her In Voice' [Mantra] 9. Sasha & Marsh 'Dead Synthy' [Anjunadeep] 10. Holly North ‘Falling' (Elif) [Ki] 11. Guy J 'Silver Lake' [Early Morning] 12. XOTTO ‘The Rainbow' [Monaberry] Happy 300th to us

In celebration of reaching the milestone of our 300th edition of the Selador Sessions, Dave's back with another Radio Therapy, plus as an added bonus, Steve has made a special SS300 Mix full of Selador classics, old and new, that will be available via the Selador Bandcamp and YouTube Pages. Head to seladorrecordings.com for further details. Tracklist.. 1. Leo Cepeha ‘Sirolo' [Monaberry] 2. Dilby ‘Closer' [Selador] 3. Four Candles & Steve Parry ‘Soul Repeat' [Selador] 4. Danny Howells ‘Cygnet' [Selador] 5. Just Her & Nolan ‘Howler'[Last Night On Earth] 6. Cortona ‘Xtaci' [Bedrock] 7. Quattrovalvole ‘Passenger Exit' (Murat Uncuoglu) [Isolate] 8. Grezzer ‘Lost Her In Voice' [Mantra] 9. Sasha & Marsh 'Dead Synthy' [Anjunadeep] 10. Holly North ‘Falling' (Elif) [Ki] 11. Guy J 'Silver Lake' [Early Morning] 12. XOTTO ‘The Rainbow' [Monaberry] Happy 300th to us

Radiotherapy plays a vital role in cancer treatment. In Europe alone, incidents of cancer are projected to rise around 20% by 2040, mainly due to an increasingly aging population. It's numbers like these that emphasize the importance of pushing boundaries in radiotherapy. With AI-optimized workflows, it's possible to speed up treatment planning and ensure highly personalized therapies and technology like auto contouring can protect healthy organs during irradiation by means of AI. This implementation, however, is often met with challenges like staff shortages and inconsistencies with data collection, highlighting the need for more efficient implementation strategies. In this episode, experts in the fields of radiotherapy and cancer treatment address the amazing headway being made in the world of radiotherapy as well as some of the key roles that current technology can play in the future.Host Sasa Mutic, President of Radiation Oncology Solutions at the Varian Business Area of Siemens Healthineers, is joined by Valery Lemmens, a member of the Board of Directors at Maastro Radiotherapy Clinic in the Netherlands and creator of the Dutch Cancer Atlas; as well as Joost Verhoeff, radiation oncologist and professor of radiotherapy at Amsterdam University Medical Center; and Indrin Chetty, Vice Chair and Director of the Division of Medical Physics at Cedars-Sinai in Los Angeles.What you'll learn in this episode:By using a digital twin, medical professionals can review existing health records and continually compare that information with patient dataWith adaptive radiotherapy, radiation dosages can be tailored to circumstances like tumor size, type, and position and proximity to vital organsThe Dutch Cancer Atlas interprets and publishes data in a context that increases awareness of regional differences in cancer incidentsThe unique role that data plays in the advancement of cancer careThe deep troves of data that already exist within radiotherapy departments can play a key role in the integration of AI into cancer treatmentsWidespread availability of data creates the opportunity for automated treatment planning and outcome predictionConnect with Sasa MuticLinkedIn Connect with Valery LemmensLinkedInConnect with Joost VerhoeffLinkedInIndrin ChettyLinkedIn Hosted on Acast. See acast.com/privacy for more information.

Dave kickstarts a new year of Radio Therapy adventures. Nothing but the good stuff. Tunes with a capital T. Let's go!

Dave kickstarts a new year of Radio Therapy adventures. Nothing but the good stuff. Tunes with a capital T. Let's go!

In today's episode, we had the pleasure of speaking with Yvonne Mowery, MD, PhD, about the phase 2 SU2C-SARC032 trial (NCT03092323) investigating the addition of pembrolizumab to preoperative radiotherapy and surgery in patients with soft-tissue sarcoma. Dr Mowey is a physician scientist and an associate professor of radiation oncology at the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.  In our exclusive interview, Dr Mowery discussed unmet needs for patients with soft-tissue sarcoma that prompted the initiation of this research, key efficacy and safety findings from the trial, and potential next steps for investigating the treatment regimen in this patient population. 

Editor in Chief Dr. Sue Yom and Associate Editor Dr. Neil Taunk, Assistant Professor of Radiation Oncology and Chief of the Gynecologic Radiation Service at the University of Pennsylvania, co-host a podcast on "Biomarker expression and impact on clinical outcomes in an international study of chemoradiation and MRI-based image-guided brachytherapy for locally advanced cervical cancer: BIOEMBRACE," with guests Dr. Supriya Chopra, Professor at Tata Memorial Centre in Mumbai, India, and Dr. Remi Nout, Professor and Head of the Department of Radiotherapy of the Erasmus Medical Center, University Medical Center, in Rotterdam, Netherlands, who were the first and last authors and both principal investigators of the BIOEMBRACE study.

The festive season is upon us and that means it's time for Dave's final Broadcast of 2024 and you're all invited. It's the Radio Therapy Christmas party. Time to get into the spirit. See you under the mistletoe x

Editor-in-Chief, Robert Amdur, MD and Resident Physician, Daniela Martir, MD discuss Partially Ablative Body Radiotherapy for Locally Advanced Unresectable Tumor. The discussion is based on a paper in PRO titled “Partially Ablative Body Radiotherapy (PABR): A Widely Applicable Planning Technique for Palliation of Locally Advanced Unresectable Tumors” (PMID 39393770).

Editor-in-Chief, Robert Amdur, MD and Resident Physician, Daniela Martir, MD discuss Partially Ablative Body Radiotherapy for Locally Advanced Unresectable Tumor. The discussion is based on a paper in PRO titled “Partially Ablative Body Radiotherapy (PABR): A Widely Applicable Planning Technique for Palliation of Locally Advanced Unresectable Tumors” (PMID 39393770).

The festive season is upon us and that means it's time for Dave's final Broadcast of 2024 and you're all invited. It's the Radio Therapy Christmas party. Time to get into the spirit. See you under the mistletoe x

Dr. Linda Duska and Dr. Domenica Lorusso discuss the practice-changing results of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which evaluated pembrolizumab plus chemoradiotherapy as treatment for previously untreated, high-risk, locally advanced cervical cancer. TRANSCRIPT  Dr. Linda Duska: Hello, I'm Linda Duska, your guest host of the ASCO Daily News Podcast today. I'm a professor of obstetrics and gynecology and serve as the associate dean for clinical research at the University of Virginia School of Medicine. On today's episode, we'll be discussing a new standard of care for previously untreated, high- risk locally advanced cervical cancer. This follows the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, which I will be referring to as KEYNOTE-A18 for the rest of this podcast, which demonstrated that pembrolizumab plus chemoradiotherapy improved both progression-free and overall survival compared to chemoradiotherapy alone. I was a co-author of this study, and I'm delighted to be joined today by the study's lead investigator, Dr. Domenica Lorusso, for today's discussion. She is also a professor of obstetrics and gynecology. She's at Humanitas University Rosano and the director of the Gynecologic Oncology Unit at the Humanitas Hospital San Pio in Milan, Italy. Our full disclosures are available in the transcript of this episode. Dr. Lorusso, it's great to be speaking with you today. Dr. Domenica Lorusso: Thank you, Linda. It's a great pleasure to be here. Thank you. Dr. Linda Duska: So I was hoping you could start us out with some context on the challenges associated with treating patients with high-risk, locally advanced cervical cancer. Dr. Domenica Lorusso: Yes. I have to make a disclosure because in my experience as a gynecologist, cervical cancer patients are the most difficult patients to treat. This is a tumor that involves young patients [who often have] small kids. This is a very symptomatic tumor. More than 50% of patients report pain. Sometimes the pain is difficult to control because there is an infiltration of the pelvic nerves and also a kind of vaginal discharge, so it's very difficult to treat the tumor. Since more than 25 years, we have the publication of 5 randomized trials that demonstrate that when we combine platinum chemotherapy to radiation treatment, we increase overall survival by 6%. This is the new standard of care – concurrent chemoradiation plus brachytherapy. This is a good standard of care because particularly modern, image-guided radiotherapy has reported to increase local control. And local control in cervical cancer translates to better overall survival. So modern radiotherapy actually is able to cure about 75% of patients. This is what we expect with chemoradiation right now. Dr. Linda Duska: So what are the key takeaways of A18? This is a really exciting trial, and you've presented it a couple of times. Tell us what are the key takeaways that you want our listeners to know. Dr. Domenica Lorusso: Linda, this is our trial. This is a trial that we did together. And you gave me the inspiration because you were running a randomized phase 2 trial exploring if the combination of pembrolizumab to concurrent chemoradiation was able to give signals of efficacy, but also was feasible in terms of toxicity. There were several clinical data suggesting that when we combine immunotherapy to radiotherapy, we can potentially increase the benefit of radiotherapy because there is a kind of synergistic effect between the two strategies. Radiotherapy works as a primer and immunotherapy works better. And you demonstrated that it was feasible to combine immunotherapy to concurrent chemoradiation. And KEYNOTE-A18 was based on this preliminary data. We randomized about 1,060 patients to receive concurrent chemoradiation and brachytherapy or concurrent chemoradiation and brachytherapy in combination with pembrolizumab followed by pembrolizumab for about two years. Why two years? Because in more than 80% of cases, recurrence in this patient population occurred during the first two years. So the duration of treatment was based on the idea to provide protection to the patient during the maximum time of risk. And the trial had the two primary endpoints, progression free and overall survival, and met both the endpoints, a significant 30% reduction in the risk of progression that was confirmed. At the 3-year follow up, the observation was even better, 0.68. So 32% reduction in the risk of progression. And more importantly, because this is a curative setting, 33% reduction in the risk of death was reported in the experimental arm when pembro was combined with chemoradiation. Dr. Linda Duska: That's amazing. I wanted to ask you, a prior similar study called CALLA was negative. Why do you think A18 was positive? Dr. Domenica Lorusso: Linda, there are several discussions about that. I had the possibility to discuss several times with the PI of CALLA, Brad Monk. The idea of Brad is that CALLA was negative because of using durvalumab instead of PD-1 inhibitor, which is pembrolizumab. I do not have exactly the same impression. My idea is that it's the kind of patient population enrolled. The patient population enrolled in KEYNOTE-A18 was really a high-risk population; 85% of that patient were node positive, where the definition of node positivity was at least 2 lymph nodes in the pelvis with a short diameter of 1.5. So, we are very confident this patient was node-positive, 55% at the grade 3 and 4 diseases. So this is really a high-risk population. I remember at the first presentation of CALLA, I was honored to discuss the CALLA trial when it was first presented at IGCS a few years ago. And when I received the forest plot of Calla, it was evident to me that in patients with stage III and node positive there was a signal of efficacy. And we have a huge number of patients with node positive. So in my opinion this is the reason why KEYNOTE-A18 is positive. Dr. Linda Duska: Yeah, I agree with you. I've thought about it a lot and I think you're right about that. The INTERLACE trial results were recently published. How should we interpret these results in the context of A18? Dr. Domenica Lorusso: So it's very difficult to compare the 2 trials. First of all, in terms of population. The population enrolled in INTERLACE is a low-risk, locally advanced but low risk population; 76% were stage II, 10% were stage I, 60% were node-negative patients. So, first of all, the population is completely different. Second is the type of radiotherapy that was provided. INTERLACE is a 10-year long trial, but in 10 years the quality and the technique of radiotherapy completely changed. Only 30% of patients in INTERLACE received what we call the modern image-guided brachytherapy, which is important because it provides local control and local control increases overall survival. And third, we read the paper. I'm not a methodologist, but there are some methodological biases in the paper. All the statistical design of the trial was based on PFS, but PFS was evaluated at physician description. And honestly, I never saw a trial that had no pre-specified timeline for radiological evaluation. It's very difficult to evaluate progression in cervical cancer because the fibrosis related to radiotherapy changes the anatomy in the pelvis. And I think that the radiological evaluation is important to address if the patient is progressing or not. Particularly, because the conclusion of CALLA is that the PFS was mainly in favor of distant metastasis. So really, it's difficult for me to understand how distant metastasis may be evaluated with the vagina visit. So really, it's very difficult to compare the two trials, but I have some concerns. And also because of toxicity in the study, unfortunately 30% of patients did not complete concurrent chemoradiation because of residual toxicity due to induction chemotherapy. So I wanted to be sure in the context of modern radiotherapy, if really induction chemo adds something to modern radiotherapy. Dr. Linda Duska: Well, I have two more questions for you. As we move immunotherapy into the front line, at least for these high risk locally advanced cervical cancer patients that were eligible for A18, what does that mean then for hopefully those few that develop recurrence in terms of second line therapy? Dr. Domenica Lorusso: Well, Linda, this is a very important question. We do not have data about immuno after immuno, but I would not completely exclude this hypothesis because in KEYNOTE-A18, the patient received treatment for a well-defined time period. And for those patients not progressing during immunotherapy, I really guess if there is a space for the reintroduction of immunotherapy at the time of recurrence. In this moment we have 30% of patients in KEYNOTE-A18 in the control arm that receive immunotherapy after progression, but still we have 11% of patients that receive immunotherapy in combination with concurrent chemoradiation and then receive, again, immunotherapy in later line of therapy. I think we need to collect these data to capture some signals and for sure we have the new drug. We have antibody drug conjugate. The trials are ongoing exploring the role of antibody drug conjugate, particularly in immune pretreated patients. So I think this is a very interesting strategy. Dr. Linda Duska: I was going to ask you, “What are the next steps,” but I think you already answered that question. You talked about the second line. If you were going to redesign a study in the frontline, what would it look like? Dr. Domenica Lorusso: Probably one question that I would like to answer – there are two questions in my opinion in KEYNOTE-A18 – one is induction immunotherapy. Linda, correct me if I'm wrong, you reported very interesting data about the immune landscape change when you use induction immunotherapy. And I think this is something that we need to explore in the future. And the second question is the duration of maintenance. Because, again, we decided for two years based only on the epidemiology of recurrence, but I guess if one year may be enough. Dr. Linda Duska: I think this sequencing question is really important, that the induction immunotherapy was actually GY017. I can't take credit for that, but I think you're right. I think the sequencing question is really important. Whether you need the concurrent IO or not is an important question. And then to your point about the 2 years, the length of the need for maintenance therapy is a question that we don't know the answer to. So there are lots of really important questions we can continue to ask. I want to thank you so much for sharing your valuable insights with us on the podcast today. You're always so thoughtful about this particular study and cervix cancer in general and also for your great work to advance the care for patients with GYN cancers. Dr. Domenica Lorusso: Thank you, Linda. It's our work - we progress together. Dr. Linda Duska: Yes. And we thank the patients as well. The over 1,000 patients that went on this trial during a pandemic. Right? Dr. Domenica Lorusso: Absolutely. Without their generosity and their trust, we would not be able to do this trial. Dr. Linda Duska: So we're very grateful to them and we thank our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you all.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:  Dr. Linda Duska @Lduska Dr. Domenica Lorusso   Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn     Disclosures:   Dr. Linda Duska: Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn Dr. Domenica Lorusso: Consulting or Advisory Role: PharmaMar, AstraZeneca, Clovis Oncology, GSK, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept, Sutro Biopharma, Novartis, Novocure, Daiichi Sankyo/Lilly Speakers' Bureau: AstraZeneca, Clovis, GSK, MSD, ImmunoGen, Seagen Research Funding (Inst.): PharmMar, Clovis, GSK, MSD, AstraZeneca, Clovis Oncology, Genmab, Seagen, Immunogen, Incyte, Roche, Pharma&, Corcept Therapeutics, Alkermes Travel, Accommodations, Expenses: AstraZeneca, Clovis, GSK, Menarini  

  Clement Manyathela speaks to Dr Heidi Hart who is an oncologist at the Vincent Palloti Hospital about what goes into radiotherapy as a treatment for cancer.See omnystudio.com/listener for privacy information.

In today's episode, supported by PDS Biotech, we had the pleasure of speaking with Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, about the role of PDS0101 (Versamune HPV) in patients with human papillomavirus type 16 (HPV16)–positive head and neck squamous cell carcinoma (HNSCC). Dr Harrington is head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research in London, United Kingdom, as well as a fellow of the Royal College of Physicians and the Royal College of Radiologists. In our exclusive interview, Dr Harrington discussed current unmet needs for patients with recurrent/metastatic HNSCC, the rationale for the continued investigation of PDS0101 plus pembrolizumab (Keytruda) in patients with HPV16-positive HNSCC, and how the ongoing phase 3 VERSATILE-003 trial may change the treatment paradigm for patients with this disease. 

Dave's back in the hot seat with the penultimate Radio Therapy Broadcast of 2024 choc full of electronic goodness. As per. Just add volume and enjoy! Tracklist.. 1. Andrew Sant & Andre Espeut ‘The Call' [Selador] 2. Delon & Jinadu ‘Vacant' [Get Physical] 3. Nandu ‘No One Else To Love' [Crib] 4. Gossip ‘Give It All Up For Love' (Tripolism) [Colombia] 5. Motip White ‘The Infinite Edge' (Elif) [When We Dip XYZ] 6. Adana Twins & Xinobi ‘Higher' (Malóne) [Watergate] 7. Sam Hopgood ‘Kill My Love' [Selador] 8. Booka Shade ‘Real Love' [Blaufield] 9. Budakid ‘Loving' Sun' (Hernan Cattaneo & Kevin Di Serna) [Flores] 10. Shiffer & Paul Brenning ‘We Care' [Innervisions] 11. Costello ‘Dream Operator' [COD3 QR] This show is syndicated & distributed exclusively by Syndicast. If you are a radio station interested in airing the show or would like to distribute your podcast / radio show please register here: https://syndicast.co.uk/distribution/registration

Endocrine diseases are prevalent in cats, and the most frequent ones are diabetes and hyperthyroidism. Hyperthyroidism in cats is a common endocrine disorder typically seen in older felines, characterized by an overproduction of thyroid hormones (T3 and T4) from an enlarged, usually benign thyroid gland. This hormone surge ramps up metabolism, leading to classic symptoms like weight loss despite an increased appetite, hyperactivity, restlessness, and a poor coat condition. Other signs may include increased thirst, vomiting, and heart murmurs or hypertension due to the cardiovascular strain. If untreated, hyperthyroidism can lead to heart disease, high blood pressure, and kidney damage. Treatment options include medication, dietary management, surgery, or radioactive iodine therapy, depending on the cat's health status and owner's preference.

Dr. Dionisia Quiroga discusses emerging approaches to personalizing locoregional treatment for breast cancer with Drs. Walter Paul Weber and Charlote Coles, who share insights on tailoring axillary surgery, escalating lymphatic surgery, and implementing hypofractionated radiotherapy. TRANSCRIPT Dr. Dionisia Quiroga: Hello, I'm Dr. Dionisia Quiroga, your guest host of the ASCO Daily News Podcast today. I'm a breast medical oncologist and assistant professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center. On today's episode, we'll be discussing emerging approaches to personalize locoregional treatment for patients with breast cancer, including many of the latest updates on axillary surgical staging, lymphatic surgery, and evidence-based radiotherapy in the treatment of breast cancer. We're very fortunate to have joining me today for this discussion Dr. Walter Paul Weber, a professor and head at the Division of Breast Surgery at the University Hospital Basel in Switzerland, and Dr. Charlotte Coles, a professor of cancer clinical oncology and the deputy head of the Department of Oncology at the University of Cambridge in the United Kingdom. Our full disclosures are available in the transcript of this episode. Dr. Weber and Dr. Coles, it's very wonderful to have you on the podcast and thank you so much for being here. Dr. Walter Paul Weber: Thank you very much for having us. Dr. Charlotte Coles: Thank you. Dr. Dionisia Quiroga: Now, for many decades prior, axillary lymph node dissection has very much been our standard of care. But recently, axillary surgeries have been able to be gradually deescalated to spare some of our patients from relative and relevant long-term morbidity. There are still some indications in which axillary lymph node dissection still remain. And therefore, we still see breast cancer-related lymphedema, a well-known sequela of the axillary surgery to continue to be prevalent. And I think it's important also to acknowledge that today there's about an estimated 1.5 million cancer survivors who deal with breast cancer-related lymphedema. Now, Dr. Weber, at the recent ASCO Annual Meeting, you and your co-presenters discussed tailoring axillary surgery, escalating lymphatic surgery and implementing evidence-based hypofractionated radiotherapy to really personalize locoregional treatment for people who've been diagnosed with breast cancer. And in addition to that, you and Dr. Coles have also published this work in the 2024 ASCO Educational Book. Can you tell us about some of the recent advances in axillary surgery and what are really the current indications for axillary dissection? Dr. Walter Paul Weber: Yes, I'm happy to do so. So as you've said, we've known for a while that we can omit axillary dissection in patients with clinically known negative breast cancer and negative sentinel nodes. We've known for about 10-15 years that we can omit axillary dissection in patients with one or two positive sentinel nodes in many patients. But what we've learned recently is that we can omit axillary dissection also in patients with one or two positive sentinel nodes who have larger primary tumors who undergo mastectomy or who have extranodal extension. This is a landmark trial that was published just a few months ago, the SENOMAC trial that established this. The remaining indications for axillary dissection are situations where you expect a heavy tumor load in the axilla. For example, when you have more than two positive sentinel nodes or you have a patient with clinically node-positive breast cancer who undergoes upfront surgery and has palpable disease or significant disease on imaging. Patients with locally advanced breast cancer, who are considered by some to be not eligible for nodal downstaging, such as patients with CN2, CN3 disease or CT4 breast cancer. And then the big group of patients who have residual disease after neoadjuvant chemotherapy in the nodes, standard of care is still axillary dissection. But we now have some real-world evidence that it's safe for selected patients with low volume nodal disease left in the nodes, mostly isolated tumor cells, to not undergo axillary dissection. So these are the remaining indications today. Dr. Dionisia Quiroga: Can you speak to situations where maybe even sentinel lymph node biopsies might be omitted? I know you spoke a little bit about the use of imaging in your work. Dr. Walter Paul Weber: Yes, this is correct. So, we started about maybe 7 or 8 years ago to omit sentinel lymph node biopsy in older patients above 70 years of age who have luminal disease, according to recommendations from the Choosing Wisely initiative. And now indeed there are several ongoing randomized trials that investigate if axillary imaging can replace surgical staging of the axilla. And the first of these trials was published recently, the SOUND trial with almost 1,500 patients, who underwent breast conserving surgery and had small tumors and all had a negative ultrasound of the axilla. And then they were randomized into a sentinel lymph node biopsy versus no axillary surgery. And that trial showed non-inferiority of the omission of sentinel lymph node biopsy in these patients. Now, it's a bit early to roll out the Choosing Wisely recommendation to all patients who have a negative ultrasound. The SOUND trial showed that about 14% had a false-negative ultrasound. So, in the control arm, they actually did have a positive sentinel node. And in patients where that one missed sentinel node makes a big difference in terms of systemic therapy, most experts would still recommend sentinel biopsy, and these are patients mainly with HER2-positive or triple-negative breast cancer or premenopausal patients or those who have G3 biology. Dr. Dionisia Quiroga: I think you bring up a very important point. Coming from the side of a breast medical oncologist, we're also very interested to see what these studies show because many of our practices are based on what we find out from our lymph node biopsies. So, I think a lot of interesting prospective studies to look at in the future. Dr. Walter Paul Weber: Absolutely. Dr. Dionisia Quiroga: One other topic we wanted to discuss was local regional management of stage four disease and particularly oligometastatic disease. And this is not a new topic of interest. We've been speaking about this for a long time in breast cancer management, but can you address some of the axillary management strategies that you currently use for stage 4 disease? Dr. Walter Paul Weber: Yes, it depends on your intention. If your intention is to cure the patient, then you would apply all the locoregional standards that apply in the curative setting, which means lymph node biopsy with or without axillary dissection. Now in a palliative situation, it's individualized. Very often you don't touch the axilla and sometimes you open it and just remove palpable disease, trying to minimize morbidity. The question of which intent you should follow is controversial; three out of the four randomized trials did not show a benefit for locoregional surgery in patients with de novo stage 4 disease. However, experts seem to disagree. The last St. Gallen consensus recommendation was in favor of the curative intent in such a patient with oligometastatic disease; 85% favored the curative intent. So there's a bit of discrepancy there, but everybody would agree, and this is what has been done in all of these trials, that if you try to cure the patient, then you should apply the curative standards of sentinel and axillary dissection that you use also in early-stage breast cancer. Dr. Dionisia Quiroga: Thank you. Now, moving on from surgical axillary management and more into lymphedema prevention and treatment. Can you speak to some of the promising advances that have happened in this field? Dr. Walter Paul Weber: Yes, so the best way to prevent lymphedema still is not to perform axillary dissection, which is the number 1 risk factor, which is all the axillary surgery de-escalation research that we've just discussed is all about. Prevention of lymphedema is one major aim of this. Now, once you indicate axillary dissection and you expect the patient to be at high risk – for example, if there are other risk factors such as obesity or neoadjuvant chemotherapy or extended regional nodal radiotherapy, then indeed there are emerging techniques that really seem to work. There is some evidence supporting it, which is categorizable as immediate lymphatic repair basically or bypass. And that is usually in a patient who undergoes axillary dissection, and also undergoes axillary reverse mapping. That allows the identification of the lymph nodes that are probably most relevant to the drainage of the lymphatic fluid from the arm. And then you can try to spare these. But if you decide, and this is effective, there is a consistent body of evidence, not phase 3 trials, but pretty consistent evidence that axillary reverse mapping works just by sparing the identified nodes. But if you decide that you have to remove these nodes as part of the radical concept of axillary dissection, then immediate lymphatic repair is also increasingly being done and is also supported by consistent evidence, even some single center randomized trials, low volume, but all consistently showing quite a striking benefit of this immediate lymphatic repair technique. There are different ways you can do it. You can either use it the microscope, and it's being done by the plastic surgeons, but it's also a simplified technique described that can be used by specialized general and breast surgeons. Both techniques seem to really work based on what we know from the studies, but also based on our common sense. Dr. Dionisia Quiroga: You talked about the procedures that can be offered to patients at time of breast surgery. And unfortunately, many of our patients maybe did not have the availability of those techniques when they undergo their initial breast cancer treatment. Once lymphedema is developed in a limb following breast cancer diagnosis, can you speak to other interventions that can be done to potentially help mitigate lymphedema? Dr. Walter Paul Weber: Right, so for patients who no longer benefit from or wish to further undergo conservative treatment of lymphedema, there are emerging procedures that are now out of my personal comfort zone because they're being performed by plastic surgeons; they use the microscope. There are two groups, the lymphovenous anastomosis and then the real vascular lymph node transfer as a free flap. And both of these procedures (there are no randomized trials yet published), but some really good ones are on the way and currently recruiting based on the evidence we have, which is over 20 observational studies all consistently again showing a benefit in terms of what you can measure in terms of centimeters or with a bioimpedance spectroscopy, or also when you ask the patients, you see quite some dramatic improvements by both of these techniques. And it's increasingly being done. Personally, I strongly believe that it works based on everything we know and understand from lymphedema development, but also prevention and treatment. So I am quite sure that in 5-10 years, we will see much more surgical treatment of patients with lymphedema by highly specialized plastic surgeons. Dr. Dionisia Quiroga: That's my hope as well. Now, another important component of local regional treatment we know is of course radiotherapy. And there have been many incredible advances in breast radiotherapy over the past decades, which has really improved cancer control and decreased side effects in our patients. Dr. Coles, you've led practice changing radiotherapy trials in the past and your research has really influenced international hypofractionation policy. Can you expand upon the emergence of hypofractionated radiation for breast cancer and the effects that it can have on our patient care? Dr. Charlotte Coles: Yes, so thank you very much, Dr. Quiroga. So I think the first thing to say is that radiotherapy hypofractionation isn't a new concept. And in fact, the breast radiotherapy hypofractionation trial started around three decades ago. And the rationale for this was the hypothesis that breast cancer is as sensitive to fraction, which is the treatments that we give, we split it into fractions, is sensitive as late responding tissue. So what does this mean? It means that the small traditional 2 Gy fraction spare tumor and normal tissues equally, so there's no advantage. So therefore, fewer fractions with a larger dose per fraction are worth testing. The problem is there's a concern that hypofractionation might increase the risk of side effects, and that includes the really important one we've been talking about, lymphedema. But we can reduce this risk by reducing the total radiotherapy dose over the whole course. But the question was by how much. So that's why randomized trials were needed. And there's been really high-quality trials with robust radiotherapy quality assurance, and they've been designed in partnership with patients. So just a very quick run through: A landmark trial was the UK START B trial. And this was a pragmatic design that compared 50 Gy in 25 fractions, which was commonly used in the south of the country with 40 Gy in 15 fractions, which was used at that time in the north [of the UK]. And this recruitment was around in the late 1990s and early 2000s. What we knew was that the three-week regimen was actually radiobiologically lower dose. And therefore the results that we got, it wasn't surprising that the 40 Gy was actually gentler on the normal tissue. So that's an advantage for patients. But what was surprising was it wasn't gentler on the tumor and non-inferiority was proven. So this suggests that overall treatment time is important for local control. So this fits with hypofractionation. Way back in 2009, 40 Gy in 15 fractions to both the breast and regional nodes became standard of care in the UK. But five-week nodal and actually breast as well remained standard of care in many countries for many years after that, a little bit to do with the fact that there were few patients treated in the START trial in terms of treating the node. So more recently we've had more randomized trials, particularly for nodal radiotherapy. And this includes the recently reported Danish SKAGEN 1 trial and also the French HypoG-01 trial, which was actually presented at ESMO in Barcelona a couple of weeks ago. So we've now got data for over 5,800 participants in really high-quality randomized trials testing three weeks and five weeks of nodal radiotherapy. And there's no statistically significant difference in late normal tissues for any of these, including lymphedema. So certainly, in my opinion and reflecting in many of the European guidelines, five-week radiotherapy is no longer indicated and three-week nodal radiotherapy is the international standard of care. So, in conclusion, the question is can we hypofractionate even further? So the UK FAST-Forward trial tested three weeks with two different dose levels of one week for the whole breast. Primary endpoint was ipsilateral breast tumor response. More than 4,000 patients participated and this was reported in 2020 with a median follow -up of six years and this was very timely because this is a time of COVID and the results showed non-inferiority for local control with similar late normal tissue side effects and we've also had other results from the UK IMPORT HIGH trial which shows that we can safely deliver a small, highly targeted team of boost simultaneously with the whole breast in all in three weeks. Finally, these two landmark trials have come together for the design of the UK FAST-Forward Boost Study led by my colleague Dr. Anna Kirby. And this is going to test three-week simultaneous integrated boost with two levels of one-week simultaneous integrated boost. And it's also going to test the safety of 5 fraction nodal radiotherapy, including the internal mammary node. Primary endpoint is ipsilateral breast tumor response, multiple normal tissue endpoints, including patient-reported outcomes of course, and the target recall is large with 4,800 participants. So, in summary, I would say that hypofractionation is efficacious, has similarly reduced toxicity. Importantly, it reduces patient burden and that's incredibly important because it means that people can get back on with their life quicker. It reduces health system costs, and also increases equity of access. So we really do need to continue to recruit and design high quality trials in this area. Dr. Dionisia Quiroga: Thank you, Dr. Coles. I think you highlight that there really aren't any downsides to looking into hypofractionated radiotherapy at this point. So excited to see what those future trials yield. And I want to thank you so much, Dr. Weber and Dr. Coles for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Walter Paul Weber: Thank you very much. Dr. Charlotte Coles: Thank you. Dr. Dionisia Quiroga: And thank you to our listeners for joining us today. Our listeners will find a link to our guests' article from the ASCO Educational Book in the transcript of this episode, as well as a link to their presentation from the most recent ASCO Annual Meeting. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Dionisia Quiroga @quirogad Dr. Walter Paul Weber Dr. Charlotte Coles Follow ASCO on social media:     @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn    Disclosures: Dr. Dionisia Quiroga: No relationships to disclose Dr. Walter Weber: Honoraria: MSD Dr. Charlotte Coles: No relationships to disclose

In the 200th episode of the Purr Podcast, Dr. Kelly and Dr. Susan are joined by the esteemed Dr. Thomas Schemerhorn to discuss feline hyperthyroidism, a common condition in older cats. They delve into the four accepted therapies for managing this endocrine disorder, offering insights into each approach's pros and cons. Sponsored by Norbrook, makers of Felanorm (methimazole) oral solution for cats, the episode also highlights the importance of bioequivalent pharmaceutical products in veterinary care. Take advantage of this milestone episode packed with expert advice on keeping hyperthyroid kitties healthy and happy!

SHIRTS ARE BACK! *Elvis & Barbara are excited to release two new shirts (along with long sleeves and hoodies) to get ready for fall! This time we have two designs, one for removable techs and one for fixed. “Just say no to brushing”- idea and the denture is from Brittany Mitchell: https://www.bonfire.com/shirt-for-removable-techs/ “Don't pull out” features art work from Charlie Barbour at CIMBdesign: (https://www.redbubble.com/people/cimbdesign/shop?asc=u). https://www.bonfire.com/shirt-for-fixed-techs/ You should be able to both shirts in your cart if you want both…. And this time the podcast logo is on the back! Just a reminder that 100% of the profits get donated to the Foundation For Dental Laboratory Technology (https://dentallabfoundation.org/). Sale ends September 14th. On September 11th in Fort Worth, Texas, the 10th annual Race For the Future (https://dentallabfoundation.org/news-events/race-for-the-future/) will take place to raise money for the Foundation For Dental Laboratory Technology (https://dentallabfoundation.org/). Barb is doing her 9th solo race and Elvis is teaming up with Mark Williamson and Bobby Kenney to form The Abutments. Go to dentallabfoundation.org and click on the DONATE TODAY button. There you need to log in or create an account. Then select “Race for the Future” and enter the name of either Barb Warner or the Abutments, then the amount you want to donate: https://fdlt.memberclicks.net/donor-form This week we talk to Charlie Barbour from the UK. Charlie comes on to talk about how though an engineering program, he found the dental laboratory industry. Getting hired at Bristol Crown (https://www.bristolcrown.com/), a lab-to -lab milling center for the ALS Dental Group (https://als-dental.com/). He starts by loading mills and scanning models, and soon noticed of how many of the crowns looked the same. Pushed by self-learning, Charlie was soon designing crowns in Exocad (https://exocad.com/) and he even started making teeth libraries for other labs in the ALS group. Going back to lab school, he had an assignment of drawing crowns and a new passion started. Now Charlie is taking his art to the next level by creating detailed and brightly colored pieces that include not only crowns, but implants, abutments, full arches, dentures, and so much more. Check out his art and get yourself a few prints: https://www.redbubble.com/people/cimbdesign/shop?asc=u Introducing Ivotion Digital Dentures (https://www.ivoclar.com/en_us/products/digital-processes/ivotion) from Ivoclar (https://www.ivoclar.com/en_us) – Experience unparalleled precision and efficiency with Ivoclar‘s state-of-the-art digital denture workflow. Ivotion is available in their patent pending monolithic disc that combines denture base and tooth materials in one seamless puck. Or if you lab needs more flexibility, Ivotion is also available as stand-alone discs - Ivotion Base, Dent and Dent Multi all in 98mm width to fit your favorite milling machine. With Ivotion you can streamline your lab's processes, reduce production time, and enhance patient satisfaction. Elevate your lab's capabilities with Ivotion Digital Dentures – where innovation meets perfection. Discover the future of dentures today with Ivoclar." Thanks for your continued support of the podcast Ivoclar. Join the GOLDEN BENCH CLUB! All you have to do is leave us a 5-star review and comment on the Apple Podcast app (or any other app and email us a screen shot) and we will read your review on the podcast and welcome you to the Golden Bench Club. This super elite club is only for the best of the best Special Guest: Charles Barbour.